SCHEMBL30997622

SCHEMBL30997622

CN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4cccc(N5CCCC5=O)n4)n3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.57
▸ WEE1 P30291 6/20 0.51
▸ FYN P06241 2/20 0.49
▸ CSF1R P07333 2/20 0.49
▸ RET P07949 2/20 0.49
▸ FGFR1 P11362 2/20 0.49
▸ FLT3 P36888 2/20 0.49
▸ CDK7 P50613 2/20 0.49
▸ CDK5 Q00535 2/20 0.49
▸ PRKAA1 Q13131 2/20 0.49
▸ CCNA2 P20248 2/20 0.49
▸ CDK2 P24941 2/20 0.49
▸ CDK9 P50750 2/20 0.49
▸ CDK6 Q00534 2/20 0.49
▸ PIK3CD O00329 1/20 0.49
▸ PRKAB2 O43741 1/20 0.49
▸ NUAK1 O60285 1/20 0.49
▸ CCNT1 O60563 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ CDK1 P06493 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29310117 1.00 SLC2A1 (0.57) SLC2A1WEE1FYNCSF1RRET
SCHEMBL29310229 0.91 SLC2A1 (0.47) SLC2A1WEE1FYNCSF1RRET
SCHEMBL30997639 0.91 SLC2A1 (0.47) SLC2A1WEE1FYNCSF1RRET
SCHEMBL30997614 0.88 SLC2A1 (0.59) SLC2A1WEE1FYNCSF1RRET
SCHEMBL29310121 0.88 SLC2A1 (0.59) SLC2A1WEE1FYNCSF1RRET
SCHEMBL29310236 0.88 BTK (0.49) SLC2A1WEE1EGFRBTKTNK2
SCHEMBL29310230 0.88 WEE1 (0.48) SLC2A1WEE1EGFRBTKTNK2
SCHEMBL30997625 0.88 SLC2A1 (0.44) SLC2A1WEE1FYNCSF1RRET
SCHEMBL30997653 0.88 SLC2A1 (0.44) SLC2A1WEE1FYNCSF1RRET
SCHEMBL29310214 0.88 SLC2A1 (0.44) SLC2A1WEE1FYNCSF1RRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B SLC2A1 4591/4885WEE1 1/4885FYN 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback